Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Staying Liquid Will Give Lyft Stock a Post-Virus Boost

By Chris Lau, InvestorPlace Contributor

LYFT stock held steady despite the company withdrawing guidance, so investors will look at cost-cuts to ensure the company’s survival.

Buy Nvidia Ahead of These Two Positive Catalysts

By Chris Lau, InvestorPlace Contributor

Despite obvious pressures from the pandemic, the Mellanox buyout approval and strong gaming demand represent undeniable catalysts for NVDA stock.

7 Smart Stocks to Watch as Volatility Stays Soaring

By Chris Lau, InvestorPlace Contributor

Investors have seven stocks to watch as a gradual re-opening of the economy resets sales expectations higher.

Why You Can Buy AbbVie At a Massive Discount

By Chris Lau, InvestorPlace Contributor

ABBV stock does not fully reflect the deep pipeline of drugs under development and the billions in future sales from two key drugs.

Why Remdesivir Clinical Studies Will Lift Gilead Sciences

By Chris Lau, InvestorPlace Contributor

GILD stock rose sharply in recent weeks as markets bet the company has a treatment against the novel coronavirus.

Load More